{"id":"NCT01986361","sponsor":"Reckitt Benckiser LLC","briefTitle":"Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method","officialTitle":"A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Onset-of-Action Study Utilizing the Double-Stopwatch Method","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2013-11-18","resultsPosted":"2017-08-24","lastUpdate":"2017-09-28"},"enrollment":122,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Pharyngitis","Sore Throat"],"interventions":[{"type":"DRUG","name":"flurbiprofen","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"flurbiprofen 8.75 mg lozenge","type":"EXPERIMENTAL"},{"label":"Placebo lozenge","type":"PLACEBO_COMPARATOR"}],"summary":"The study's purpose is to demonstrate the onset of action, i.e., time to meaningful pain relief in patients with pharyngitis, of flurbiprofen 8.75 mg lozenge using the Double-Stopwatch Method (DSW).","primaryOutcome":{"measure":"Kaplan-Meier Estimates for Time to Meaningful Pain Relief","timeFrame":"up to 3 hours post dose on Day 1","effectByArm":[{"arm":"Flurbiprofen 8.75 mg Lozenge","deltaMin":42.917,"sd":null},{"arm":"Placebo Lozenge","deltaMin":null,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["29381110"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":101},"commonTop":["Nausea","Headache","Pyrexia","Abdominal discomfort","Diarrhoea"]}}